What's the Best Psychedelic Therapy for Depression? A Research-Backed Guide

Is There a "Best" Psychedelic Therapy for Depression?

No single psychedelic therapy has been crowned best for depression, but a few stand out for different reasons. Ketamine therapy has the largest real-world evidence base and is the only option widely available today, with most patients improving within about two weeks. Psilocybin has the deepest research pipeline among the classic psychedelics, with small trials showing strong results and larger controlled trials showing more modest ones. Esketamine is the only FDA-approved option, though it is delivered as in-clinic medication management. MDMA and LSD are earlier-stage and, for now, mostly confined to research settings.

No head-to-head trial has compared these treatments directly, and they are measured on different symptom scales and tested in different populations. So the most useful thing you can do is weigh them across four dimensions: how much evidence each option has, how fast it works, how it is delivered, and whether you can actually access it. For many people the real decision is less about which compound is theoretically best and more about which one you can access safely and legally where you live.

What Is Psychedelic Therapy for Depression?

Psychedelic therapy pairs a psychoactive medicine with structured psychological support: preparation before dosing, a guided or monitored dosing session, and integration afterward to help make sense of the experience. The goal is not only the acute drug effect but the therapeutic process built around it.

The medicines studied for depression fall into two broad groups. Classic serotonergic psychedelics like psilocybin, LSD, ayahuasca, and DMT act mainly on serotonin receptors. Ketamine and its cousin esketamine are dissociative anesthetics that work through a different, glutamate-based pathway. Ketamine is not a classic psychedelic, but it is used in the same therapy model and belongs in the conversation.

How It Differs From Antidepressants

Standard antidepressants like SSRIs are taken daily and typically take four to six weeks to begin working.⁶ Psychedelic-style treatments are given as a small number of sessions rather than a daily pill, and several of them tend to act faster. They are usually considered when first-line antidepressants have not worked well enough, not as a replacement for talking to your prescriber about what you are already taking.

The Main Types of Psychedelic Therapy for Depression

Four options come up most often, and they differ far more in access than in headline results. Other psychedelics have an earlier and thinner depression research base: ayahuasca and 5-MeO-DMT have been studied mostly in small or open-label trials, while DMT now has an early placebo-controlled trial showing a rapid antidepressant signal, and all remain investigational.⁷⁻⁹

How to read this table: These are reported figures from separate studies, not a head-to-head. The studies use different symptom scales (PHQ-9, MADRS, QIDS), different populations, and different definitions of response and remission. Treat it as context for a conversation with a clinician, not a straight ranking.

Ketamine Therapy

Ketamine therapy uses racemic ketamine, which can be prescribed off-label and, in an at-home telehealth model, taken at home with remote clinical support. It has the deepest real-world track record of the group. In Mindbloom's peer-reviewed study of at-home patients, 81.8% saw a clinically meaningful improvement in depression symptoms and 56.6% met the stricter response threshold on the PHQ-9 after a full course.¹ It is worth noting that racemic ketamine is a different formulation from esketamine, and in the largest head-to-head meta-analysis, racemic ketamine produced roughly 2.2 times the response and 2.5 times the remission of esketamine.¹⁰ For more on the mechanism, see our guide to how ketamine helps depression.

Esketamine (Spravato)

Esketamine, sold as Spravato, is FDA-approved for treatment-resistant depression, but there is genuine debate over whether it belongs in a discussion of psychedelic therapy at all. Under an FDA risk-management program it is delivered as in-clinic medication management: every dose is given in a certified clinic with on-site monitoring, without the preparation, intention-setting, set and setting, or integration that define the psychedelic-therapy model.⁵ In its pivotal trial it improved depression when paired with a newly started oral antidepressant, though the effect size was small.¹¹ A real-world study using the PHQ-9 found remission around 18% over three to six months.¹² We compare the two formats in more detail in Mindbloom vs. Spravato.

Psilocybin (Magic Mushrooms)

Psilocybin, the active compound in psychedelic mushrooms, has the strongest depression evidence base among the classic psychedelics, and it is the field's real contender for treating depression. In the largest, best-controlled trials the results are meaningful but modest: a treatment-resistant trial reported about 37% response and 29% remission on the MADRS.¹³ A separate controlled trial in general major depression reported sustained response near 42%.¹⁷ Smaller trials have reported response as high as about 70%.¹⁴ The leading meta-analysis rated the overall evidence as moderate and cautioned that these smaller, open-label results are likely inflated by participants' expectations.⁴ Psilocybin is not FDA-approved for depression and remains available only through clinical trials or, in a few jurisdictions, licensed centers.

MDMA and LSD

MDMA and LSD are earlier and thinner stories for depression. MDMA has not been tested as a primary depression treatment; the depression signal comes from its Phase 3 trials in PTSD, where it improved depression symptoms as a secondary outcome.¹⁵ LSD for depression rests largely on a single modern randomized trial with a modest and statistically fragile effect.¹⁶ Both are investigational and, for now, available only through research settings.

How the Options Compare on Published Results

On efficacy, the picture is closer than the headlines suggest. In the at-home ketamine study, 81.8% of patients had a clinically meaningful improvement and 56.6% met the stricter response threshold on the PHQ-9.¹ Across the psilocybin depression trials, reported response spans roughly 37% in a treatment-resistant trial on the MADRS to about 70% in a moderate-to-severe trial on the QIDS scale.¹³⁻¹⁴ A large controlled trial in general major depression reported sustained response near 42%.¹⁷ Ketamine's real-world response sits squarely inside that range, delivered from home.

The larger difference is in the sheer amount of evidence. The at-home ketamine depression base spans roughly 15,000 patients across three peer-reviewed studies, among the largest real-world evidence bases for any depression treatment given outside a clinic.¹⁻³ The leading psilocybin meta-analysis we reviewed pooled about 436 participants, and the bases for MDMA, LSD, ayahuasca, and 5-MeO-DMT are thinner still.⁴

How Fast Does Psychedelic Therapy Work?

Fast onset is one of the biggest advantages psychedelic-style treatments have over standard antidepressants, which typically take four to six weeks to begin working.⁶ Ketamine therapy shows it at scale: in the at-home study, 70.2% of patients had a clinically meaningful improvement in depression symptoms after just two sessions, roughly two weeks.¹ The classic psychedelics can act quickly too, though so far only in small trials. Single-dose psilocybin has lowered depression scores as early as the day after dosing, with many patients responding within the first week.¹³⁻¹⁴ In an early controlled trial, a single dose of DMT produced substantial symptom reductions the day after dosing.⁹ The practical difference is not which compound acts fastest. It is that ketamine delivers this rapid response in a large, real-world population you can start now, while the psilocybin and DMT results come from small trials you would have to enroll in to reach.

Does the Benefit Last?

This is where the treatment models differ. Many psilocybin depression trials tested a single dose, and in their published follow-ups the benefit tended to lessen over the following months, for example in the six-month data from the psilocybin-versus-antidepressant trial.¹⁴ Ketamine therapy is instead structured as a defined multi-session course with published second-course outcomes: in Mindbloom's largest study, 84% of patients who received a second course maintained or recovered clinically significant improvement.² This is a difference in treatment model rather than a claim that one lasts longer than the other.

Which Option Is Right for You?

The right choice depends less on chasing the highest number and more on your situation:

• If you have treatment-resistant depression: All of these options are studied primarily in people who have not responded to standard antidepressants. Esketamine is the FDA-approved route for TRD but requires in-clinic visits, while at-home ketamine therapy offers a comparable evidence-backed option you can access remotely.
• If access and cost matter most: Ketamine therapy is the only option in this group that is broadly available today, and it is generally far less expensive per course than in-clinic esketamine.
• If you want the classic psychedelic experience specifically: Psilocybin is the most-studied classic psychedelic for depression, but you would typically need a clinical trial or a licensed center to access it legally.

Whatever you are considering, the decision belongs in a conversation with a qualified clinician who knows your history.

How to Start Treatment Today

Availability, not FDA status, is usually the deciding factor. Psilocybin, MDMA, and LSD remain investigational, which for most people means a clinical trial is the only legal path. Esketamine is available but requires repeated in-clinic visits with monitoring. Ketamine therapy is the one option that can be prescribed and started at home today. Mindbloom, the largest at-home psychedelic therapy provider in the U.S., delivers this model under clinician supervision, currently with ketamine, from screening through integration.¹ It is not FDA-approved, but it is accessible now, and that combination of evidence and access is what makes it a practical starting point for many people. You can review current treatment options and pricing before deciding.

Safety and Who Should Avoid Psychedelic Therapy

Across the peer-reviewed at-home ketamine studies, side effects were infrequent and generally mild, affecting roughly 3 to 5 percent of patients, with serious adverse events in fewer than 0.1 percent of cases.¹ Any of these treatments should be undertaken with clinical screening and support, not on your own. Psychedelic and dissociative therapies are generally not appropriate for people with certain cardiovascular conditions or a personal or family history of psychosis, and they are not a substitute for emergency care. A qualified provider will screen for these factors before treatment.

Finding the Right Fit

Psychedelic therapy for depression is a fast-moving field, and psilocybin in particular has real promise. But most options remain small in scale and hard to access. Ketamine therapy offers benefit in the same range as the psychedelic trials, backed by one of the largest published evidence bases in the field, with relief often within about two weeks, and it can be done from home today. That mix of evidence, speed, and access is a reasonable place to start a conversation with a clinician.